CytomX Advances Varseta-M Pipeline with Expanded Regeneron Alliance — CytomX Therapeutics, Inc.

Event summary

CytomX expects Phase 1 monotherapy update for Varseta-M in advanced colorectal cancer (CRC) by year-end 2026, with registrational study planned for 1H 2027.
Phase 1/2 chemotherapy combination study for Varseta-M in 2nd line mCRC to initiate in Q4 2026.
Regeneron collaboration expanded with $37M target selection payment for two additional programs, potentially reaching up to $4B in total milestones.
Q2 2026 revenue dropped to $1.4M from $18.7M YoY due to completed performance obligations and lower research activities.

The big picture

CytomX is accelerating its lead program, Varseta-M, through expanded clinical trials while strengthening its strategic alliances. The Regeneron collaboration expansion underscores the value of CytomX's PROBODY platform in developing next-generation immunotherapies. With a cash runway extending into 2028 and a focus on high-unmet-need indications, CytomX is positioning itself for potential late-stage catalyst events in oncology.

What we're watching

Clinical Milestones: Whether CytomX can deliver positive Phase 1 data for Varseta-M by year-end and secure FDA alignment on registrational study design.
Strategic Alliances: How the expanded Regeneron collaboration will impact CytomX's pipeline development and financial runway beyond 2028.
Market Positioning: The pace at which CytomX can differentiate Varseta-M in the competitive ADC space for colorectal and other gastrointestinal cancers.